Tender Offer - Pentwater Capital Management LP

Form Type: SCHEDULE 13D/A

Filing Date: 2025-01-13

Corporate Action: Tender-offer

Type: Update

Accession Number: 000090266425000190

Filing Summary: This document is an Amendment No. 3 to the Schedule 13D previously filed by Pentwater Capital Management LP regarding Poseida Therapeutics, Inc. The amendment highlights that the Pentwater Funds tendered their shares of Common Stock in a Tender Offer that expired on January 7, 2025, and were accepted for payment on January 8, 2025. Following the tender offer, a merger took place on January 8, 2025, where Merger Sub merged with Poseida Therapeutics, Inc., resulting in Poseida as the surviving corporation. Consequently, Pentwater Capital Management LP no longer owns any securities of the Issuer, leading to the termination of the Pentwater Support Agreement upon the merger's effective time. The document includes details regarding the listing of shares and transactions over the past sixty days, indicating no prior transactions were executed by the Reporting Persons during this timeframe.

Document Link: View Document